21,045 research outputs found
sj-docx-1-tah-10.1177_20406207231165857 – Supplemental material for Considerations for shared decision management in previously untreated patients with hemophilia A or B
No full textSupplemental material, sj-docx-1-tah-10.1177_20406207231165857 for Considerations for shared decision management in previously untreated patients with hemophilia A or B by Jan Astermark, Jan Blatný, Christoph Königs, Cédric Hermans, Victor Jiménez-Yuste and Daniel P. Hart in Therapeutic Advances in Hematology</p
Managing haemophilia for life: 4th haemophilia global summit
No full textThe 4th Haemophilia Global Summit was held in Potsdam, Germany, in September 2013 and brought together an international faculty of haemophilia experts and delegates from multidisciplinary backgrounds. The programme was designed by an independent Scientific Steering Committee of haemophilia experts and explored global perspectives in haemophilia care, discussing practical approaches to the optimal management of haemophilia now and in the future. The topics outlined in this supplement were selected by the Scientific Steering Committee for their relevance and potential to influence haemophilia care globally. In this supplement from the meeting, Jan Astermark reviews current understanding of risk factors for the development of inhibitory antibodies and discusses whether this risk can be modulated and minimized. Factors key to the improvement of joint health in people with haemophilia are explored, with Carlo Martinoli and Víctor Jiménez-Yuste discussing the utility of ultrasound for the early detection of haemophilic arthropathy. Other aspects of care necessary for the prevention and management of joint disease in people with haemophilia are outlined by Thomas Hilberg and Sébastian Lobet, who highlight the therapeutic benefits of physiotherapy and sports therapy. Riitta Lassila and Carlo-Federico Perno describe current knowledge surrounding the risk of transmission of infectious agents via clotting factor concentrates. Finally, different types of extended half-life technology are evaluated by Mike Laffan, with a focus on the practicalities and challenges associated with these products. © 2014 John Wiley & Sons Ltd
sj-docx-1-tah-10.1177_20406207221085202 – Supplemental material for International consensus recommendations on the management of people with haemophilia B
No full textSupplemental material, sj-docx-1-tah-10.1177_20406207221085202 for International consensus recommendations on the management of people with haemophilia B by Daniel P. Hart, Davide Matino, Jan Astermark, Gerard Dolan, Roseline d’Oiron, Cédric Hermans, Victor Jiménez-Yuste, Adriana Linares, Tadashi Matsushita, Simon McRae, Margareth C. Ozelo, Sean Platton, Darrel Stafford, Robert F. Sidonio and Andreas Tiede in Therapeutic Advances in Hematology</p
Jan Kapr's contribution to contemporary music : an essay about a composer and teacher
No full textThis creative project is a treatise on a leading personality of Czechoslovakian musical life, the composer, Jan Kapr. The author discusses the following:1. The complicated development of Kapr's career and work, 2. Kapr's method of organization of musical material in a composition, as described in his book Constants,3. His former and current style which is demonstrated in two of his compositions, Concert Variations, for flute and string orchestra and Testimonies for four solo instruments,4. Two of his recent works, Exercises for Gydli and the Symphony No. 7, Country of Childhood.Thesis (M.A.
Going Beyond Counting First Authors in Author Co-citation Analysis
No full textThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
ELEVEN FACES OF JAN GOGOL, JR.
No full textAuthor Jan Rendl in his thesis attempts to look at the world of ideas and educator Jan
Gogola ml. through the eleven chapters in which each chapter somehow characterizes itself by Jan Gogola ml. and each of them somehow determines its creative ideas of it through the metaphor of a football match when Jan Gogola, with its characters, movies himself a teammate, as well as defensively. It gives goals with their situations as well as occasionally digging his opponents ankles.
Jan Gogola ml. thus embodies one stage of the Department of Documentary Film at FAMU, which often stands at the intersection between teaching activities and Karel Vachek among students who applied by them during their seminars psychological methods that work must be peculiarly associated with the author of the film
Partnering to change the world for people with haemophilia: 6(th) Haemophilia Global Summit, Prague, Czech Republic, 24-26(th) September 2015
No full textThe 6(th) Haemophilia Global Summit was held in Prague, Czech Republic, in September 2015. The programme was designed by an independent Scientific Steering Committee of haemophilia experts and aimed to share optimal management strategies for haemophilia at all life stages, explore recent potential advances in the management of haemophilia A and B and discuss challenges in haemophilia care. In this supplement from the meeting, Dan Hart reviews the lessons that can be learnt from cost-constrained environments with regard to improving care for people with haemophilia globally. Sébastien Lobet discusses the importance of physical activity for optimising care and Roseline d'Oiron and Jan Blatný consider the role of real-world data in understanding the effect of treatment in a clinical setting over the long term and the true impact of treatment on the day-to-day life of the patient. Gili Kenet addresses the current challenges relating to the optimal management of prophylaxis, and Gerry Dolan and Cedric Hermans discuss the value of pharmacokinetic (PK) parameters in informing treatment decisions. Cedric Hermans and Valérie Libotte explore the importance of considering social and occupational development factors as an integral part of haemophilia care, and Jan Astermark reviews key strategies to predict and prevent inhibitor development
Dr. Jan French – Faculty Author Interview
No full textDr. Jan French, Assistant Professor of Anthropology, discusses her new book, Legalizing Identities: Becoming Black or Indian in Brazil’s Northeast, which shows how law can successfully serve as the impetus for the transformation of cultural practices and collective identity
Jan Bernátek - organ works
No full textThis graduation thesis provides a more detailed view on compositoins of Jan Bernátek.The aim is to present this less well-known temporary czech author,who makes use of the organ in the majority of his work
From theory to practice: Applying current clinical knowledge and treatment strategies to the care of hemophilia A patients with inhibitors
No full textTwo bypassing agents are currently available to circumvent the need for factor FVIII in hemophilia A patients with inhibitors: the activated prothrombin complex FEIBA VH and recombinant activated factor VII (NovoSeven (R)). Both products are highly effective in controlling bleeding in the presence of inhibitory alloantibodies, yet their hemostatic efficacy can be unpredictable. As the results of the FEIBA NovoSeven (R) Comparative (FENOC) study illustrate, patients may respond better to one bypassing agent than the other. Furthermore, guidelines from an expert panel reflect that responsiveness to bypassing therapy may change from one bleed to the next in the same patient and even from hour to hour during the course of a single bleeding event. These findings underscore the need to have both bypassing products available to treat bleeding episodes in inhibitor patients, to frequently evaluate the efficacy of hemostasis during the course of a bleeding event, and to switch products early if the response to treatment is unsatisfactory. (C) 2008 Elsevier Ltd. All rights reserved
- …
